We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Getein Biotech, Inc.

Getein Biotech, Inc. is a fully integrated in vitro diagnostic company that develops, manufactures and distributes an... read more Featured Products: More products

Download Mobile App





Getein Introduces New MAGICL 6000 Chemiluminescence Immunoassay Analyzer at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Print article
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)

Getein Biotech, Inc. (Nanjing, China) is introducing new POC solutions, including analyzers and rapid tests, at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Getein is introducing MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer, with optimal choice for mid to high-workflow laboratories that require a one-step chemiluminescence solution. Highly productive and compact, the instrument enables fully automated operation and provides the fastest testing speed of any device of its size. Getein is also showcasing Metis 600, a bench-top two in one immuno-hemanalysis and hematology modular system.

Among its range of POC platforms being highlighted at the event is the Getein 1600 fully-automated immunofluorescence quantitative analyzer which combined with bar-coded, ready-to-use strip cassettes, delivers accurate testing results in minutes. In conjunction with dedicated immunofluorescence test kits, the Getein 1600 automates the detection and quantification of markers for cardiovascular disease, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor and thyroid in a biological sample. Visitors to the company’s booth at MEDICA 2022 can also experience the Getein 1180 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnosis of laboratory and POC testing and is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc.

Also on display at MEDICA 2022 are the Getein 1160 multi-channel POCT analyzer which has four incubation channels and one emergency test channel, along with a constant test environment with 32℃ to ensure more accurate test results. The Getein 1160 is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc. Alongside the Getein 1160, the company is demonstrating the Getein 208 hand-held integrated system that works with dedicated test kits made by Getein. Getein 208 is intended to detect and quantify specific chemical components in human blood serum, plasma, whole blood, capillary blood and urine samples through dry chemistry and fluorescence immunoassay. Getein is also showcasing rapid tests at MEDICA 2022, including its Monkeypox Virus Real-time PCR Kit which is used for the qualitative detection of MPV in serum or lesion exudate samples.

Related Links:
Getein Biotech, Inc. 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The test can find tRNA fragments unique to Parkinson’s disease before patients even have symptoms (Photo courtesy of Shutterstock)

Rapid Blood Test Identifies Pre-Symptomatic Patients with Parkinson’s Disease

Currently, no reliable blood test exists for diagnosing Parkinson’s disease. Instead, physicians rely on observing a patient's movements, but this qualitative method has an error rate of 20%-25% and can... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.